Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M

Xtant Medical Holdings, Inc.

2025-Q1 EPS reported $0.00 revenue$32,904,000

Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.
Adjusted EBITDA $3.0M vs loss $1.0M; cash from operations $1.3M vs use of $5.8M.
FY2025 revenue guidance raised to $127-131M (8-12% growth) from prior $126-130M.
Launched Trivium next-generation DBM allograft; elevated Mark Schallenberger to COO.
Terminated investor rights agreement with OrbiMed; completed secondary share sale led by Nantahala.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.